Low-dose diclofenac (Zorvolex) for pain

Medical Letter on Drugs and Therapeutics

Volumn 56, Issue 1437, 2014, Pages 19-20

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELECOXIB; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUCONAZOLE; PLACEBO;

AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; PAIN; RECOMMENDED DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACUTE PAIN; ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; HUMANS;

EID: 84895450421     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. A Gibofsky et al. Lower-dose diclofenac submicron particle capsules provide early and sustained acute patient pain relief in a phase 3 study. Postgrad Med 2013; 125:130.
2. A Gibofsky et al. A phase 3 study of lower-dose diclofenac submicron particle capsules demonstrates effective pain relief in patients with osteoarthritis. Osteoarthritis Cartilage 2013; 21(4) suppl:S267. Abs. 518.
3. Drugs for pain. Treat Guidel Med Lett 2013; 11:31.
4. C Young and MC Hochberg. Safety of lower-dose diclofenac submicron particle capsules dosed up to 12 weeks in patients with osteoarthritis. Arthritis Rheum 2013; 65(10) suppl:S915. Abs. 2149.
5. Inhibitors and inducers of CYP enzymes and P-glycoprotein. Med Lett Drugs Ther 2013; 55:e44.
6. Approximate wholesale acquisition cost (WAC). Source: Analy$ource Monthly (Selected from FDB MedKnowledge™) February 5, 2014. Reprinted with permission by FDB, Inc. All rights reserved. ©2014. www.fdbhealth.com/policies/drug-pricing-policy. Actual retail prices may be higher.